PIK3CA and endometrial cancer: In the SAP, four patients (cohort 1 PIK3CA mutation-positive endometrial cancer, n = 1; cohort 3 ovarian clear cell carcinoma, n = 3) had confirmed PR, suggesting that TAS-117 has antitumor activity in patients with selected advanced solid cancers.